Orchard therapeutics acquires rare disease gene therapy portfolio from GSK

“This acquisition further strengthens our position as a global leader in gene therapy for rare diseases and underlines our commitment to transform the lives of patients through innovative gene therapies” Mark Rothera, President and Chief Executive Officer.

click here for our recent press release

click here to see our gene therapy pipeline
Bringing transformative gene therapies to life